scholarly journals Lipolytic Postbiotic from Lactobacillus paracasei Manages Metabolic Syndrome in Albino Wistar Rats

Molecules ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 472
Author(s):  
Ali Osman ◽  
Nashwa El-Gazzar ◽  
Taghreed N. Almanaa ◽  
Abdalla El-Hadary ◽  
Mahmoud Sitohy
Keyword(s):  
Metabolic Syndrome ◽  
Lipid Metabolism ◽  
Lipolytic Activity ◽  
Control Level ◽  
Serum Triglyceride ◽  
Positive Control ◽  
Lactobacillus Paracasei ◽  
Total Serum ◽  
Albino Rats ◽  
Total Serum Cholesterol

The current study investigates the capacity of a lipolytic Lactobacillus paracasei postbiotic as a possible regulator for lipid metabolism by targeting metabolic syndrome as a possibly safer anti-obesity and Anti-dyslipidemia agent replacing atorvastatin (ATOR) and other drugs with proven or suspected health hazards. The high DPPH (1,1-diphenyl-2-picrylhydrazyl) and ABTS [2,2′-azino-bis (3-ethyl benzothiazoline-6-sulphonic acid)] scavenging activity and high activities of antioxidant enzyme such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-px) of the Lactobacillus paracasei postbiotic (cell-free extract), coupled with considerable lipolytic activity, may support its action against metabolic syndrome. Lactobacillus paracasei isolate was obtained from an Egyptian cheese sample, identified and used for preparing the postbiotic. The postbiotic was characterized and administered to high-fat diet (HFD) albino rats (100 and 200 mg kg−1) for nine weeks, as compared to atorvastatin (ATOR; 10 mg kg−1). The postbiotic could correct the disruption in lipid metabolism and antioxidant enzymes in HFD rats more effectively than ATOR. The two levels of the postbiotic (100 and 200 mg kg−1) reduced total serum lipids by 29% and 34% and serum triglyceride by 32–45% of the positive control level, compared to only 25% and 35% in ATOR’s case, respectively. Both ATOR and the postbiotic (200 mg kg−1) equally decreased total serum cholesterol by about 40% and 39%, while equally raising HDL levels by 28% and 30% of the positive control. The postbiotic counteracted HFD-induced body weight increases more effectively than ATOR without affecting liver and kidney functions or liver histopathology, at the optimal dose of each. The postbiotic is a safer substitute for ATOR in treating metabolic syndrome.

Effect and Mechanism of Virechana Karma (Therapeutic Purgation) Over Fructose-Induced Metabolic Syndrome

2015 ◽  
Vol 21 (3) ◽  
pp. 194-201 ◽  
Author(s):  
Ashutosh Chaturvedi ◽  
Prasanna N. Rao ◽  
M. Ashvini Kumar ◽  
B. Ravishankar ◽  
Niranjan Rao ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Fasting Blood Glucose ◽  
Animal Experiments ◽  
Serum Triglyceride ◽  
Positive Control ◽  
The Body ◽  
Control Group ◽  
Albino Rats ◽  
The Metabolic Syndrome ◽  
Obesity And Diabetes

Background. Panchakarma (biopurification methods) is one of the modes of ayurveda to treat disorders of the body. Virechana karma (therapeutic purgation), one among the Panchakarma, is a purification process that is commonly used to treat metabolic disorders like obesity and diabetes mellitus. Hence this study was planned to provide evidence through animal experiments. Methods. Albino rats were subject to Virechana karma (therapeutic purgation) to evaluate the influence of therapy and its mechanism over fructose-induced metabolic syndrome. Results. Results show that Virechana is effective in the management of the metabolic syndrome with decrease in the fecal fat content, fasting blood glucose, serum triglyceride, and reduced fatty changes in liver, heart, and kidney in comparison with the positive control group. Conclusion. Experimental evaluation showed decrease in fatty acid in the storage like liver, kidney, heart, and muscle adipose tissue can indirectly increase the insulin sensitivity in insulin receptor present at skeletal muscles.

Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients

1993 ◽  
Vol 128 (3) ◽  
pp. 251-258 ◽  
Author(s):  
Per H Andersen ◽  
Bjørn Richelsen ◽  
Jens Bak ◽  
Ole Schmitz ◽  
Niels S Sørensen ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Serum Insulin ◽  
Whole Body ◽  
Glucose Disposal ◽  
Total Serum ◽  
Total Serum Cholesterol ◽  
Diabetic Patients ◽  
Obese Patients ◽  
Short Term ◽  
Glucose And Lipid Metabolism

In a short-term (eight days) double-blind crossover study involving 10 obese patients, the effects of dexfenfluramine on glucose and lipid metabolism were examined. The protocol comprised whole body in vivo measurements (hyperinsulinemic euglycemic clamp in combination with indirect calorimetry) and in vitro studies of isolated adipocytes (lipolysis and glucose transport). All study participants were weight stable during the study period (103.1±3.2, placebo vs 103.3±3.1 kg, dexfenfluramine, NS). The following parameters were significantly reduced after dexfenfluramine treatment: fasting levels of plasma glucose (6.2±0.2 vs 5.7±0.2 mmol/l, p<0.01), serum insulin (168.0±14.5 vs 138.9±7.9 pmol/l, p<0.05), serum C-peptide (0.68±0.03 vs 0.58±0.02 nmol/l, p<0.05) and total serum cholesterol (6.07±0.41 vs 5.48±0.38 mmol/l, p< 0.01). In the basal state glucose oxidation rate was significantly reduced by 36% (p<0.001), whereas non-oxidative glucose disposal was significantly increased by 41% (p<0.01), following dexfenfluramine treatment. Insulin-stimulated (2 mU·kg−1·min−1) glucose disposal rate tended to be increased (18%, p=0.10) after dexfenfluramine. In conclusion, dexfenfluramine possesses beneficial regulatory effects on glucose and lipid metabolism in non-diabetic obese patients, independently of weight loss.

THE LIPID METABOLISM IN YOUNG AND MEDIUM MEN AGE WITH MYOCARDIAL INFARCTION AND RECURRENT EPISODES OF ISCHEMIA

2021 ◽  
pp. 66-72
Author(s):  
Golikov A.V. ◽  
Epifanov S.Yu. ◽  
Reiza V.A.
Keyword(s):  
Myocardial Infarction ◽  
Lipid Metabolism ◽  
High Density Lipoproteins ◽  
Total Serum ◽  
Control Group ◽  
Total Serum Cholesterol ◽  
Study Group ◽  
Type I ◽  
Prevention Measures ◽  
Recurrent Myocardial Infarction

Relevance. Dyslipidemia is considered one of the main risk factors for the development of recurrent myocardial infarction and early postinfarction angina. Aim. To evaluate the features of lipid metabolism in acute and subacute myocardial infarction in men under 60 years old with recurrent episodes of ischemia (recurrent myocardial infarction and/or early postinfarction angina) to search for new approaches to improve prevention measures. Material and methods. The study included men aged 19-60 years old with type I myocardial infarction. Patients are divided into two age-comparable groups: I - the study group, with recurrent myocardial infarction - 68 patients; II - control, without it - 427 patients. A comparative assessment of lipid metabolism parameters and their dynamics in selected groups were performed. Results. The study group differed in higher levels of total serum cholesterol (6.17±1.78 mmol/l) from the control group (5.56±1.28 mmol/l; p=0.02) at the end of the third week of disease, its dynamics during the observation period (I: 9.1%; p<0.0001; II: -1.8%; p<0.0001) and the dynamics of the atherogenic coefficient (I: -4.7.1; p=0.02; II: 6.3%; p<0.0001). In both groups, the group showed an increase in lipoproteins of low (I: 33.1; p=0.02; II: 45.5%; p<0.0001) and very low density (I: 275.8; p=0,0004; II: 233.4%; p<0.0001), atherogenic indices, decrease: triglycerides (I: -31.8%; p=0.02; II: -1.7%; p<0.0001) and high-density lipoproteins (I: -0.6%; p=0.02; II: -6.1%; p<0.0001). Conclusions. The group with recurrent ischemia is characterized by more pronounced hypercholesterolemia at the end of the subacute period of myocardial infarction in comparison with the control group due to an increase in the concentrations of atherogenic lipid metabolism fractions. The dynamics of indices and the coefficient of atherogenicity during this period is multidirectional, which requires additional study.

scholarly journals Altered Adipose Tissue DNA Methylation Status in Metabolic Syndrome: Relationships Between Global DNA Methylation and Specific Methylation at Adipogenic, Lipid Metabolism and Inflammatory Candidate Genes and Metabolic Variables

2019 ◽  
Vol 8 (1) ◽  
pp. 87 ◽  
Author(s):  
Daniel Castellano-Castillo ◽  
Isabel Moreno-Indias ◽  
Lidia Sanchez-Alcoholado ◽  
Bruno Ramos-Molina ◽  
Juan Alcaide-Torres ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Dna Methylation ◽  
Adipose Tissue ◽  
Lipid Metabolism ◽  
Environmental Factors ◽  
Metabolic Diseases ◽  
Methylation Status ◽  
Serum Triglyceride ◽  
Positive Association ◽  
Global Dna Methylation

Metabolic syndrome (MetS) has been postulated to increase the risk for type 2 diabetes, cardiovascular disease and cancer. Adipose tissue (AT) plays an important role in metabolic homeostasis, and AT dysfunction has an active role in metabolic diseases. MetS is closely related to lifestyle and environmental factors. Epigenetics has emerged as an interesting landscape to evaluate the possible interconnection between AT and metabolic disease, since it can be modulated by environmental factors and metabolic status. The aim of this study was to determine whether MetS has an impact on the global DNA methylation pattern and the DNA methylation of several genes related to adipogenesis (PPARG, PPARA), lipid metabolism (RXRA, SREBF2, SREBF1, SCD, LPL, LXRb), and inflammation (LRP1 C3, LEP and TNF) in visceral adipose tissue. LPL and TNF DNA methylation values were significantly different in the control-case comparisons, with higher and lower methylation respectively in the MetS group. Negative correlations were found between global DNA methylation (measured by LINE-1 methylation levels) and the metabolic deterioration and glucose levels. There were associations among variables of MetS, BMI, and HOMA-IR with DNA methylation at several CpG positions for the studied genes. In particular, there was a strong positive association between serum triglyceride levels (TG) with PPARA and LPL methylation levels. TNF methylation was negatively associated with the metabolic worsening and could be an important factor in preventing MetS occurrence according to logistic regression analysis. Therefore, global DNA methylation and methylation at specific genes related to adipogenesis, lipid metabolism and inflammation are related to the etiology of MetS and might explain in part some of the features associated to metabolic disorders.

scholarly journals Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)

PLoS ONE ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. e54242 ◽  
Author(s):  
Susanne Strohmaier ◽  
Michael Edlinger ◽  
Jonas Manjer ◽  
Tanja Stocks ◽  
Tone Bjørge ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Serum Cholesterol ◽  
Cancer Incidence ◽  
Total Serum ◽  
Total Serum Cholesterol ◽  
The Metabolic Syndrome ◽  
Cancer Project

scholarly journals Evaluation of some biochemical changes in the serum of phensedyl addicts of Gaibandha District, Bangladesh

2014 ◽  
Vol 20 ◽  
pp. 57-65
Author(s):  
Md Rashidul Hasan ◽  
Parvez Hassan ◽  
Md Abdul Jalil Miah
Keyword(s):  
Serum Cholesterol ◽  
Biochemical Parameters ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Hdl Cholesterol ◽  
Total Serum ◽  
Total Serum Cholesterol ◽  
P Value

Context: Abuse of the drug, Phensedyl like any other drug might exert adverse effects on vital organs of th e h u m an body like liver, kidney and heart. Objectives: To determine the effects of Phensedyl intake on the serum biochemical parameters of the addicts in order to access for damages of vital human organs like liver, kidney and heart. Materials and Methods: Study population consisted of 127 male Phensedyl addicts within the ages of 18–55 years of defined criteria from Gaibandha district, a Northern part of Bangladesh, during July 2009 to December 2011. Fifty (50) non-drug dependent healthy men of matched age, height, and socioeconomic status were included as controls from the same community. Biochemical parameters analyzed were – Serum creatinine, SGOT, SGPT and Lipid profiles (total serum cholesterol (TC), Serum triglyceride (TG), serum high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol determined by semiautomatic biochemistry analyzer using commercially available kits Results: Abuse of Phensedyl appears not to hamper the normal renal and liver function in most of the addicts even after 8 years of Phensedyl intake irrespective of age except in case of 4 abusers. Serum total cholesterol (TC) remained almost unchanged among the addicts abusing Phensedyl for less than 8 years. But very strikingly, addicts taking Phensedyl for more than 8 years had higher trends in serum cholesterol i.e. more than 200 ml/dl. Of the addict’s, 44.36% abusing Phensedyl for less than 8 years had normal triglyceride (TG) values whereas, in 45.66% addicts abusing the drug for more than 8 years had clinically very significantly elevated triglyceride levels, which was also found to be statistically very significant (p value =0.0001), indicating the risk of developing cardiac diseases. Of the total addicts 53.53% had low levels of HDL cholesterol, which is clinically and statistically found to be very significant (p value =0.002). Of the addict’s 43% taking the drug for less than 8 years had normal LDL levels but significantly elevated values were recorded in 34% of the abusers who had been taking the drug for more than 8 years. Conclusion: Long time (> 8 years) Phensedyl abusers are at the high risk of developing Brain stroke, Coronary Heart Disease (CHD), Ischemic stroke or transient ischemic attack (TIA) as there is the triad of: Elevated LDL cholesterol, Low HDL cholesterol and elevated Triglyceride. DOI: http://dx.doi.org/10.3329/jbs.v20i0.17656 J. bio-sci. 20: 57-65, 2012

Enzymic serum cholesterol measurement with a basic autoanalyzer and Du Pont aca method.

1978 ◽  
Vol 24 (9) ◽  
pp. 1624-1627 ◽  
Author(s):  
B Fingerhut
Keyword(s):  
Serum Cholesterol ◽  
Continuous Flow ◽  
Flow System ◽  
Serum Triglyceride ◽  
Total Serum ◽  
Total Serum Cholesterol ◽  
Serum Triglyceride Concentration ◽  
Clinically Significant ◽  
Significant Interference ◽  
Cholesterol Measurement

Abstract I compared enzymic methods for total serum cholesterol as used with discrete (Du Pont aca and reagent packs) and continuous-flow (Boehringer Mannheim reagents and the Technicon AuotAnalyzer I) analysis of normal, icteric, and lipemic sera. The regression equation for 24 clear, non-icteric sera was: y (continuous flow) = 0.944x (aca) + 10.69; r = 0.971, Syx +/- 53.7 mg of cholesterol per liter. The continuous-flow system indicated no significant interference when as much as 350 mg of bilirubin was added per liter. Results with the aca method indicated a decrease in apparent cholesterol of about 5 mg/liter per milligram of added bilirubin. Serial diluting of lipemic sera resulted in falsely higher values with the aca method but no clinically significant effect on results with the AutoAnalyzer procedure. Apparent cholesterol as measured with the aca became proportionately greater than AutoAnalyzer values with increasing serum triglyceride concentration.

Sign in / Sign up

Export Citation Format

Share Document